Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTAVERA vs ESTROSTEP FE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no known contraindications, who have achieved menarche)
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone acetate: hydrolyzed to norethindrone, then metabolized by reduction and glucuronidation.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Ethinyl estradiol: 97-98% bound to albumin and SHBG; norethindrone acetate: 91-95% bound to albumin and SHBG.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Ethinyl estradiol: 2.3-3.6 L/kg; norethindrone acetate: 1.5-2.5 L/kg. Indicates extensive tissue distribution.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
Oral: Ethinyl estradiol ~45% (first-pass metabolism); norethindrone acetate ~64%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Use is contraindicated in patients with severely impaired renal function (GFR <30 m L/min/1.73 m²) due to potential for fluid retention and hyperkalemia.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function; no specific dose adjustment guidelines are established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Safety and efficacy have not been established in pediatric patients below 16 years of age. Post-pubertal adolescents may be dosed as adults, with careful consideration of risks (e.g., bone density).
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Not indicated for use in women over 65 years due to lack of efficacy and safety data, and increased risk of cardiovascular and thrombotic events.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use this product.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thromboembolic disorders, cardiovascular disease (MI, stroke), hypertension, gallbladder disease, hepatic neoplasia, lipid effects, glucose intolerance, headache, breakthrough bleeding, depression, contact lens intolerance, fluid retention, hereditary angioedema.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, pregnancy, hypersensitivity to any component.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
No specific food interactions are reported for Estrostep Fe. Grapefruit juice may slightly increase estrogen levels but is not considered clinically significant. There are no dietary restrictions. However, patients should maintain a consistent intake of folic acid if planning pregnancy; iron supplements can be taken with food to reduce GI upset.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects from sex hormones. Second/third trimester: feminization of male fetus, potential for urogenital malformations, and long-term reproductive tract effects. Postnatal: possible increased risk of childhood cancers.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Excreted in breast milk in small amounts (estrogen M/P ratio ~0.2, progestin M/P ratio ~0.6). May reduce milk quantity and quality. Use caution; generally not recommended. No adverse effects reported in infants at typical doses.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Contraindicated; no dose adjustment needed because drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not applicable due to contraindication.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Estrostep Fe is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. It is unique among OCPs for its step-up estrogen regimen (20, 30, 35 mcg EE) intended to mimic natural menstrual cycle. Clinicians should note that it is not FDA-approved for acne treatment, though it is often used off-label; only Estrostep (non-Fe) is approved for acne. The iron (ferrous fumarate) in the last 7 tablets is a placebo. It is a low-dose pill; missed doses more likely cause breakthrough bleeding. Contraindications include smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Counsel patients to take at same time daily; if missed, follow standard missed pill protocol.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
Take one pill at the same time each day. The first 21 pills contain active hormones; the last 7 pills are iron tablets (not hormones).,If you miss a pill, refer to the package insert or contact your healthcare provider. Use backup contraception (condoms) if pills are missed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Estrostep Fe does not protect against sexually transmitted infections (STIs). Always use condoms for STI prevention.,Smoking while using this pill increases risk of serious cardiovascular events. Do not smoke.,Contact your doctor if you experience signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron in the last 7 pills is to help with iron levels but does not provide hormonal contraception during that week.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTAVERA vs ESTROSTEP FE, answered by our medical review team.
ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. ESTROSTEP FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTAVERA and ESTROSTEP FE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. The standard adult dose of ESTROSTEP FE is: One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTAVERA and ESTROSTEP FE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. ESTROSTEP FE is classified as Category C. Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiov. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.